Alterity Therapeutics Limited (PRNAF)
USD 0.01
(0.0%)
USD 0.01
(0.0%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 | -12.47 Million AUD | 19.81% |
| 2023 | -15.56 Million AUD | 55.13% |
| 2022 | -34.68 Million AUD | -23.67% |
| 2021 | -28.04 Million AUD | -206.12% |
| 2020 | -9.16 Million AUD | 36.37% |
| 2019 | -14.39 Million AUD | 5.48% |
| 2018 | -15.23 Million AUD | 30.38% |
| 2017 | -21.88 Million AUD | 23.46% |
| 2016 | -28.59 Million AUD | 18.09% |
| 2015 | -34.9 Million AUD | -2.17% |
| 2014 | -34.16 Million AUD | -172.37% |
| 2013 | -12.54 Million AUD | -135.02% |
| 2012 | -5.33 Million AUD | 37.59% |
| 2011 | -8.55 Million AUD | -63.61% |
| 2010 | -5.22 Million AUD | -21.42% |
| 2009 | -4.3 Million AUD | 61.71% |
| 2008 | -11.24 Million AUD | -51.78% |
| 2007 | -7.4 Million AUD | 26.07% |
| 2006 | -10.01 Million AUD | 53.1% |
| 2005 | -21.36 Million AUD | 27.33% |
| 2004 | -29.4 Million AUD | -751.33% |
| 2003 | -3.45 Million AUD | 3.72% |
| 2002 | -3.58 Million AUD | 47.67% |
| 2001 | -6.85 Million AUD | -53.37% |
| 2000 | -4.46 Million AUD | -22347845.0% |
| 1999 | -20.00 AUD | 0.0% |
| 1998 | -20.00 AUD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | -12.24 Million AUD | 21.33% |
| 2024 Q4 | -12.47 Million AUD | 1.26% |
| 2024 Q3 | -12.63 Million AUD | -3.23% |
| 2024 FY | -12.47 Million AUD | 19.81% |
| 2024 Q2 | -12.24 Million AUD | 0.0% |
| 2023 Q3 | -15.67 Million AUD | 38.08% |
| 2023 Q4 | -15.56 Million AUD | 0.68% |
| 2023 FY | -15.56 Million AUD | 55.13% |
| 2023 Q2 | -25.3 Million AUD | 0.0% |
| 2023 Q1 | -25.3 Million AUD | 27.04% |
| 2022 Q1 | -36.97 Million AUD | -31.82% |
| 2022 Q4 | -34.68 Million AUD | 0.17% |
| 2022 FY | -34.68 Million AUD | -23.67% |
| 2022 Q2 | -36.96 Million AUD | 0.04% |
| 2022 Q3 | -34.74 Million AUD | 5.99% |
| 2021 Q1 | -35.04 Million AUD | -282.43% |
| 2021 Q3 | -28.07 Million AUD | 19.87% |
| 2021 FY | -28.04 Million AUD | -206.12% |
| 2021 Q2 | -35.04 Million AUD | 0.0% |
| 2021 Q4 | -28.04 Million AUD | 0.1% |
| 2020 Q2 | -12.17 Million AUD | 0.0% |
| 2020 Q1 | -12.17 Million AUD | 15.43% |
| 2020 Q3 | -9.19 Million AUD | 24.49% |
| 2020 Q4 | -9.16 Million AUD | 0.36% |
| 2020 FY | -9.16 Million AUD | 36.37% |
| 2019 Q3 | -14.39 Million AUD | -71.77% |
| 2019 FY | -14.39 Million AUD | 5.48% |
| 2019 Q4 | -14.39 Million AUD | 0.0% |
| 2019 Q1 | -8.38 Million AUD | 44.98% |
| 2019 Q2 | -8.38 Million AUD | -0.0% |
| 2018 FY | -15.23 Million AUD | 30.38% |
| 2018 Q4 | -15.23 Million AUD | 0.0% |
| 2018 Q3 | -15.23 Million AUD | 23.48% |
| 2018 Q2 | -19.91 Million AUD | 0.0% |
| 2018 Q1 | -19.91 Million AUD | 9.02% |
| 2017 Q1 | -28.34 Million AUD | 0.88% |
| 2017 FY | -21.88 Million AUD | 23.46% |
| 2017 Q4 | -21.88 Million AUD | 0.0% |
| 2017 Q3 | -21.88 Million AUD | 22.78% |
| 2017 Q2 | -28.34 Million AUD | 0.0% |
| 2016 FY | -28.59 Million AUD | 18.09% |
| 2016 Q4 | -28.59 Million AUD | 0.0% |
| 2016 Q2 | -29.05 Million AUD | 0.0% |
| 2016 Q1 | -29.05 Million AUD | 16.76% |
| 2016 Q3 | -28.59 Million AUD | 1.6% |
| 2015 Q2 | -29.05 Million AUD | 0.0% |
| 2015 FY | -34.9 Million AUD | -2.17% |
| 2015 Q1 | -29.05 Million AUD | 14.97% |
| 2015 Q3 | -34.9 Million AUD | -20.16% |
| 2015 Q4 | -34.9 Million AUD | 0.0% |
| 2014 Q1 | -18.46 Million AUD | -47.16% |
| 2014 FY | -34.16 Million AUD | -172.37% |
| 2014 Q4 | -34.16 Million AUD | 0.0% |
| 2014 Q3 | -34.16 Million AUD | -85.08% |
| 2014 Q2 | -18.46 Million AUD | 0.0% |
| 2013 Q4 | -12.54 Million AUD | 0.0% |
| 2013 FY | -12.54 Million AUD | -135.02% |
| 2013 Q3 | -12.54 Million AUD | -41.87% |
| 2013 Q2 | -8.84 Million AUD | 0.0% |
| 2012 Q2 | -6.74 Million AUD | 0.0% |
| 2012 Q4 | -5.33 Million AUD | 0.0% |
| 2012 FY | -5.33 Million AUD | 37.59% |
| 2011 FY | -8.55 Million AUD | -63.61% |
| 2011 Q4 | -8.83 Million AUD | 0.0% |
| 2011 Q2 | -2.88 Million AUD | 0.0% |
| 2010 FY | -5.22 Million AUD | -21.42% |
| 2010 Q4 | -5.22 Million AUD | 0.0% |
| 2010 Q2 | -8.37 Million AUD | 0.0% |
| 2009 Q2 | -7.85 Million AUD | 0.0% |
| 2009 FY | -4.3 Million AUD | 61.71% |
| 2009 Q4 | -4.3 Million AUD | 0.0% |
| 2008 Q4 | -11.24 Million AUD | 0.0% |
| 2008 Q2 | -9.17 Million AUD | 0.0% |
| 2008 FY | -11.24 Million AUD | -51.78% |
| 2007 Q4 | -7.4 Million AUD | 0.0% |
| 2007 FY | -7.4 Million AUD | 26.07% |
| 2007 Q2 | -11.54 Million AUD | 0.0% |
| 2006 Q2 | -15.71 Million AUD | 0.0% |
| 2006 Q4 | -10.01 Million AUD | 0.0% |
| 2006 FY | -10.01 Million AUD | 53.1% |
| 2005 Q4 | -21.36 Million AUD | 0.0% |
| 2005 FY | -21.36 Million AUD | 27.33% |
| 2005 Q2 | -26.93 Million AUD | 0.0% |
| 2004 Q4 | -29.4 Million AUD | 0.0% |
| 2004 Q2 | -5.61 Million AUD | 0.0% |
| 2004 FY | -29.4 Million AUD | -751.33% |
| 2003 Q4 | -3.45 Million AUD | 0.0% |
| 2003 Q2 | -1.44 Million AUD | 0.0% |
| 2003 FY | -3.45 Million AUD | 3.72% |
| 2002 FY | -3.58 Million AUD | 47.67% |
| 2001 FY | -6.85 Million AUD | -53.37% |
| 2000 FY | -4.46 Million AUD | -22347845.0% |
| 1999 FY | -20.00 AUD | 0.0% |
| 1998 FY | -20.00 AUD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| ContraFect Corporation | -6.02 Million USD | -107.1% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| Ember Therapeutics, Inc. | 200.43 Thousand USD | 6326.471% |
| THC Farmaceuticals, Inc. | 139.8 Thousand USD | 9026.669% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| CNBX Pharmaceuticals Inc. | 1.21 Million USD | 1128.088% |
| Eiger BioPharmaceuticals, Inc. | 15.76 Million USD | 179.172% |
| Kadimastem Ltd | -253.1 Thousand USD | -4830.755% |
| Zenith Capital Corp. | 10.06 Thousand USD | 124104.769% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | 3569.417% |
| NDT Pharmaceuticals Inc. | -647.00 USD | -1928777.898% |
| Oncotelic Therapeutics, Inc. | 12.8 Million USD | 197.449% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | 3205.604% |
| RegeneRx Biopharmaceuticals, Inc. | 1.15 Million USD | 1180.104% |
| Santhera Pharmaceuticals Holding AG | -6.3 Million USD | -97.951% |
| Propanc Biopharma, Inc. | 927.18 Thousand USD | 1445.991% |
| Qrons Inc. | 351.42 Thousand USD | 3651.19% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | 560.746% |
| Sigyn Therapeutics, Inc. | 2.38 Million USD | 623.037% |
| Accustem Sciences Inc. | -733.97 Thousand USD | -1600.302% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| EV Biologics, Inc. | 1.36 Million USD | 1012.288% |
| Affymax, Inc. | -5.59 Million USD | -122.974% |
| American Oriental Bioengineering, Inc. | 60.54 Million USD | 120.612% |
| Arch Therapeutics, Inc. | 5.64 Million USD | 320.946% |
| AXIM Biotechnologies, Inc. | 5.5 Million USD | 326.828% |
| Burzynski Research Institute, Inc. | -1310.00 USD | -952559.542% |
| Biomind Labs Inc. | 711.4 Thousand USD | 1854.26% |
| Capstone Therapeutics Corp. | 20.27 Million USD | 161.55% |
| Mosaic ImmunoEngineering Inc. | 1 Million USD | 1338.428% |
| CytoDyn Inc. | 20.26 Million USD | 161.592% |
| Evofem Biosciences, Inc. | 42.79 Million USD | 129.163% |
| IMV Inc. | 7.67 Million USD | 262.699% |
| Genus plc | 190.6 Million USD | 106.548% |
| Halberd Corporation | 144.72 Thousand USD | 8723.379% |
| Helix BioMedix, Inc. | -2.57 Million USD | -385.591% |
| Nanobac Pharmaceuticals, Incorporated | 4.11 Million USD | 403.054% |
| LadRx Corporation | -2.03 Million USD | -512.818% |
| Marizyme, Inc. | 18.56 Million USD | 167.208% |
| NanoSphere Health Sciences Inc. | -9268.34 USD | -134550.218% |
| Emmaus Life Sciences, Inc. | 30.55 Million USD | 140.845% |
| PsyBio Therapeutics Corp. | 134.63 Thousand USD | 9369.112% |
| Q BioMed Inc. | 4.06 Million USD | 407.385% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | 2064.812% |
| Enzolytics Inc. | 981.65 Thousand USD | 1371.305% |
| CSL Limited | 10.52 Billion USD | 100.119% |
| Skye Bioscience, Inc. | -5.72 Million USD | -118.126% |
| SQZ Biotechnologies Company | -36.23 Million USD | 65.561% |
| Therapeutic Solutions International, Inc. | 860.24 Thousand USD | 1550.738% |
| VioQuest Pharmaceuticals, Inc. | 2.23 Million USD | 658.174% |
| WPD Pharmaceuticals Inc. | 164.5 Thousand USD | 7686.114% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | 276.494% |
| Enzon Pharmaceuticals, Inc. | -47.01 Million USD | 73.454% |
| Nymox Pharmaceutical Corporation | 680 Thousand USD | 1935.271% |
| NovAccess Global Inc. | 2.17 Million USD | 672.873% |
| HST Global, Inc. | 96.79 Thousand USD | 12993.329% |
| SYBLEU INC | 473.71 Thousand USD | 2734.467% |
| RVL Pharmaceuticals plc | 12.94 Million USD | 196.399% |
| Alpha Cognition Inc. | -183.78 Thousand USD | -6690.345% |
| AVAX Technologies, Inc. | -5.9 Million USD | -111.408% |
| Mesoblast Limited | 55.85 Million USD | 122.342% |
| MultiCell Technologies, Inc. | 90.04 USD | 13860428.743% |
| Intellipharmaceutics International Inc. | 2.24 Million USD | 656.581% |
| Acro Biomedical Co., Ltd. | 19.86 Thousand USD | 62916.933% |
| Neon Bloom, Inc. | 622.36 Thousand USD | 2105.232% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Pharming Group N.V. | 109.8 Million USD | 111.366% |
| Curative Biotechnology, Inc. | 2.2 Million USD | 666.755% |
| GB Sciences, Inc. | 1.74 Million USD | 814.229% |
| argenx SE | -2.02 Billion USD | 99.385% |
| Resverlogix Corp. | 6.45 Million USD | 293.456% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| Nuo Therapeutics, Inc. | -673.08 Thousand USD | -1754.114% |
| MetaStat, Inc. | - USD | Infinity% |
| Northwest Biotherapeutics, Inc. | 43.43 Million USD | 128.733% |
| Provectus Biopharmaceuticals, Inc. | 1.99 Million USD | 724.182% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -8.83 Million USD | -41.176% |
| ONE Bio Corp. | 9.04 Million USD | 238.051% |
| Genscript Biotech Corporation | -1.06 Billion USD | 98.824% |
| Cotinga Pharmaceuticals Inc. | -18.31 Thousand USD | -68028.835% |
| Wesana Health Holdings Inc. | 206.21 Thousand USD | 6151.8% |
| Agentix Corp. | 37.63 Thousand USD | 33263.721% |
| Adynxx, Inc. | - USD | Infinity% |
| BioStem Technologies, Inc. | 4.47 Million USD | 379.066% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | 201.25 Thousand USD | 6301.039% |
| Cell Source, Inc. | 9.23 Million USD | 235.181% |
| ProtoKinetix, Incorporated | -20.4 Thousand USD | -61051.705% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | 2064.812% |
| Itoco Inc. | 228.3 Thousand USD | 5566.302% |
| Rasna Therapeutics, Inc. | 135.98 Thousand USD | 9277.095% |
| Pathfinder Cell Therapy, Inc. | 4.95 Million USD | 351.762% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| Alseres Pharmaceuticals, Inc. | 7.7 Million USD | 261.95% |
| Nascent Biotech, Inc. | -249.62 Thousand USD | -4899.535% |
| Rebus Holdings, Inc. | 305 Thousand USD | 4191.751% |
| ImmunoCellular Therapeutics, Ltd. | 4.45 Million USD | 380.004% |
| Mobile Lads Corp. | 484.23 Thousand USD | 2677.244% |
| International Stem Cell Corporation | 2.59 Million USD | 581.847% |
| Bioxytran, Inc. | 1.89 Million USD | 757.209% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | 20095.578% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | 672.233% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | 3.43 Million USD | 463.42% |
| Adhera Therapeutics, Inc. | 8.55 Million USD | 245.912% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | 772.6 Thousand USD | 1715.29% |
| Innovation Pharmaceuticals Inc. | -1.25 Million USD | -898.387% |
| Neutra Corp. | 52.18 Thousand USD | 24013.695% |
| Windtree Therapeutics, Inc. | -2.48 Million USD | -401.4% |
| PureTech Health plc | -167.19 Million USD | 92.536% |
| Coeptis Therapeutics, Inc. | -244.9 Thousand USD | -4995.726% |
| IXICO plc | -4.44 Million USD | -180.787% |
| IntelGenx Technologies Corp. | 13.21 Million USD | 194.408% |
| Gelesis Holdings, Inc. | 54.85 Million USD | 122.752% |
| CSL Limited | 10.52 Billion USD | 100.119% |
| Cellectis S.A. | -43.81 Million USD | 71.519% |